Statin use is associated with reduced risk of histologic subtypes of esophageal cancer: A nested case-control analysis

Gastroenterology

Volumn 146, Issue 3, 2014, Pages 661-668

  Alexandre, Leo ^a,b   Clark, Allan B ^a   Bhutta, Hina Y ^b   Holt, Sean ^c   Lewis, Michael P N ^a,b   Hart, Andrew R ^a,b  

^a UNIVERSITY OF EAST ANGLIA   (United Kingdom)

^b NORFOLK AND NORWICH UNIVERSITY HOSPITAL   (United Kingdom)

^c Roundwell Medical Centre   (United Kingdom)

Author keywords

Esophagus; HMG CoA; Squamous Cell Carcinoma; Tumor

Indexed keywords

ACETYLSALICYLIC ACID; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; NONSTEROID ANTIINFLAMMATORY AGENT; PROTON PUMP INHIBITOR;

AGED; ALCOHOL CONSUMPTION; ARTICLE; BODY MASS; CANCER REGISTRY; CANCER RISK; CONTROLLED STUDY; DATA BASE; DRUG DOSE REGIMEN; DRUG MEGADOSE; DRUG USE; ESOPHAGEAL ADENOCARCINOMA; ESOPHAGEAL SQUAMOUS CELL CARCINOMA; FEMALE; HIGH RISK POPULATION; HISTOLOGY; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; POPULATION; PRIORITY JOURNAL; RISK ASSESSMENT; RISK REDUCTION; SMOKING; TREATMENT DURATION; UNITED KINGDOM;

ESOPHAGUS; HMG-COA; SQUAMOUS CELL CARCINOMA; TUMOR;

ADENOCARCINOMA; AGED; AGED, 80 AND OVER; ANTICARCINOGENIC AGENTS; CASE-CONTROL STUDIES; COHORT STUDIES; ESOPHAGEAL NEOPLASMS; FEMALE; FOLLOW-UP STUDIES; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; LOGISTIC MODELS; MALE; MIDDLE AGED; NEOPLASMS, SQUAMOUS CELL; RETROSPECTIVE STUDIES; RISK FACTORS;

EID: 84894300706     PISSN: 00165085     EISSN: 15280012     Source Type: Journal    
DOI: 10.1053/j.gastro.2013.11.046     Document Type: Article

References (35)

1. A. Jemal, F. Bray, and M.M. Center et al. Global cancer statistics CA Cancer J Clin 61 2011 69 90
2. J. Powell, C.C. McConkey, and E.W. Gillison et al. Continuing rising trend in oesophageal adenocarcinoma Int J Cancer 102 2002 422 427
3. M.B. Cook, W.H. Chow, and S.S. Devesa Oesophageal cancer incidence in the United States by race, sex, and histologic type, 1977-2005 Br J Cancer 101 2009 855 859
4. P. van Hagen, M.C. Hulshof, and J.J. van Lanschot et al. Preoperative chemoradiotherapy for esophageal or junctional cancer N Engl J Med 366 2012 2074 2084
5. M.S. Katz Therapy insight: potential of statins for cancer chemoprevention and therapy Nat Clin Pract Oncol 2 2005 82 89
6. O.O. Ogunwobi, and I.L. Beales Statins inhibit proliferation and induce apoptosis in Barrett's esophageal adenocarcinoma cells Am J Gastroenterol 103 2008 825 837
7. M.R. Sadaria, A.E. Reppert, and J.A. Yu et al. Statin therapy attenuates growth and malignant potential of human esophageal adenocarcinoma cells J Thorac Cardiovasc Surg 142 2011 1152 1160
8. P.C. Konturek, G. Burnat, and E.G. Hahn Inhibition of Barret's adenocarcinoma cell growth by simvastatin: involvement of COX-2 and apoptosis-related proteins J Physiol Pharmacol 58 Suppl 3 2007 141 148
9. J. Shi, J. Zhu, and H. Zhao et al. Mevalonate pathway is a therapeutic target in esophageal squamous cell carcinoma Tumour Biol 34 2012 429 435
10. J.A. Kaye, and H. Jick Statin use and cancer risk in the General Practice Research Database Br J Cancer 90 2004 635 637
11. G.D. Friedman, E.D. Flick, and N. Udaltsova et al. Screening statins for possible carcinogenic risk: up to 9 years of follow-up of 361,859 recipients Pharmacoepidemiol Drug Saf 17 2008 27 36
12. D.M. Nguyen, H.B. El-Serag, and L. Henderson et al. Medication usage and the risk of neoplasia in patients with Barrett's esophagus Clin Gastroenterol Hepatol 7 2009 1299 1304
13. J. Hippisley-Cox, and C. Coupland Unintended effects of statins in men and women in England and Wales: population based cohort study using the QResearch database BMJ 340 2010 c2197
14. D.M. Nguyen, P. Richardson, and H.B. El-Serag Medications (NSAIDs, statins, proton pump inhibitors) and the risk of esophageal adenocarcinoma in patients with Barrett's esophagus Gastroenterology 138 2010 2260 2266
15. Y. Vinogradova, C. Coupland, and J. Hippisley-Cox Exposure to statins and risk of common cancers: a series of nested case-control studies BMC Cancer 11 2011 409
16. F. Kastelein, M.C. Spaander, and K. Biermann et al. Nonsteroidal anti-inflammatory drugs and statins have chemopreventative effects in patients with Barrett's esophagus Gastroenterology 141 2011 2000 2008 quiz e13-e14
17. E.D. Kantor, L. Onstad, and P.L. Blount et al. Use of statin medications and risk of esophageal adenocarcinoma in persons with Barrett's esophagus Cancer Epidemiol Biomarkers Prev 21 2012 456 461
18. I.L. Beales, I. Vardi, and L. Dearman Regular statin and aspirin use in patients with Barrett's oesophagus is associated with a reduced incidence of oesophageal adenocarcinoma Eur J Gastroenterol Hepatol 24 2012 917 923
19. I.L. Beales, I. Vardi, and L. Dearman et al. Statin use is associated with a reduction in the incidence of esophageal adenocarcinoma: a case control study Dis Esophagus 26 2013 838 846
20. S.W. Lai, K.F. Liao, and H.C. Lai et al. Atorvastatin correlates with decreased risk of esophageal cancer: a population-based case-control study from Taiwan Libyan J Med 7 2012
21. J.R. Siewert, and K. Ott Are squamous and adenocarcinomas of the esophagus the same disease? Semin Radiat Oncol 17 2007 38 44
22. J. Lagergren, R. Bergstrom, and A. Lindgren et al. Symptomatic gastroesophageal reflux as a risk factor for esophageal adenocarcinoma N Engl J Med 340 1999 825 831
23. T.L. Vaughan, S. Davis, and A. Kristal et al. Obesity, alcohol, and tobacco as risk factors for cancers of the esophagus and gastric cardia: adenocarcinoma versus squamous cell carcinoma Cancer Epidemiol Biomarkers Prev 4 1995 85 92
24. A.G. Renehan, M. Tyson, and M. Egger et al. Body-mass index and incidence of cancer: a systematic review and meta-analysis of prospective observational studies Lancet 371 2008 569 578
25. C.C. Abnet, N.D. Freedman, and F. Kamangar et al. Non-steroidal anti-inflammatory drugs and risk of gastric and oesophageal adenocarcinomas: results from a cohort study and a meta-analysis Br J Cancer 100 2009 551 557
26. M. Hashibe, P. Boffetta, and V. Janout et al. Esophageal cancer in Central and Eastern Europe: tobacco and alcohol Int J Cancer 120 2007 1518 1522
27. T. Walley, and A. Mantgani The UK General Practice Research Database Lancet 350 1997 1097 1099
28. A.M. Walker Identification of esophageal cancer in the General Practice Research Database Pharmacoepidemiol Drug Saf 20 2011 1159 1167
29. S.S. Jick, J.A. Kaye, and C. Vasilakis-Scaramozza et al. Validity of the general practice research database Pharmacotherapy 23 2003 686 689
30. H. El-Serag, C. Hill, and R. Jones Systematic review: the epidemiology of gastro-oesophageal reflux disease in primary care, using the UK General Practice Research Database Aliment Pharmacol Ther 29 2009 470 480
31. F.L. Zhang, and P.J. Casey Protein prenylation: molecular mechanisms and functional consequences Annu Rev Biochem 65 1996 241 269
32. Y. Takai, T. Sasaki, and T. Matozaki Small GTP-binding proteins Physiol Rev 81 2001 153 208
33. L.A. Garcia Rodriguez, J. Lagergren, and M. Lindblad Gastric acid suppression and risk of oesophageal and gastric adenocarcinoma: a nested case control study in the UK Gut 55 2006 1538 1544
34. A.G. Mainous 3rd, R. Baker, and C.J. Everett et al. Impact of a policy allowing for over-the-counter statins Qual Prim Care 18 2010 301 306
35. L.A. Garcia Rodriguez, and S. Perez Gutthann Use of the UK General Practice Research Database for pharmacoepidemiology Br J Clin Pharmacol 45 1998 419 425